Hologic to buy Gen-Probe for $3.7B
April 30, 2012 by MassDevice staff
Hologic agrees to pay $82.75 per share for molecular diagnostics firm Gen-Probe in a deal worth $3.7 billion.
Hologic (NSDQ:HOLX) agreed to pay about $3.7 billion for molecular diagnostics maker Gen-Probe (NSDQ:GPRO) in a cash-and-debt deal expected to close during the 2nd half of the year.
Hologic said it expects the deal to add 20¢ to its adjusted earnings per share in the first year following the deal's completion. The deal will drive about $75 million in cost savings as the companies integrate in the 3 years after the merger.
Sign up to get our free newsletters delivered straight to your inbox
Similar entries
"In addition, the combined company expects to have strong free cash flows, which will be used primarily to reduce debt with the expectation to return to pre-transaction leverage levels within 3 years," according to a press release.
- Show full page
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- A day in the life: A pediatric neurosurgeon's vision
- Medical Device Tax: Are Conservatives' goals hampering repeal efforts?
- Personal health record use by adolescents
- Can Johnson & Johnson fire on all cylinders again?
- U.S. FDA to require proof of IEC 60601-1 3rd Edition in summer 2013
- A cure for coffee breath?
- A Goldilocks approach to leaky blood vessels: Not too stiff, but not too loose
- Optimizing electronic medication administration records
- A bold new vision for Meditech
- Medtech storytelling in the era of comparative effectiveness
Navigation
NEWS
ALung pursues Chinese approval for Hemolung
ALung Technologies says it's going for a Chinese regulatory nod for its Hemolung respiratory assist...
Legal: Patient's lawyer says Intuitive Surgical's training is all about "control"
An attorney for a plaintiff suing robot-assisted surgical systems maker Intuitive Surgical says the...
Can a smartphone help spot a stroke? | MassDevice.com On Call
The American Stroke Assn. and partners release the Spot a Stroke F.A.S.T. smartphone app to help...
Chest docs include Covidien's superDimension lung biopsy device in guidelines
The lung biopsy device acquired by Covidien in its superDimension acquisition is included in new...
Medtronic hits 52-week high on Q4, FY2013 results
Investors sent Medtronic shares to a 52-week high yesterday after the world's largest medical device...
